{'fraction_non_alphanumeric': 0.03358992302309307, 'fraction_numerical': 0.013296011196641007, 'mean_word_length': 5.1373390557939915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Regulation of Experimental Autoimmune Neuritis by Transforming Growth Factor-β1

Abstract Experimental autoimmune neuritis (EAN) is a T-cell-mediated autoimmune disease characterized by demyelination and mononuclear cell infiltration of the peripheral nervous system. It is induced in Lewis rats by administration of myelin P 2 protein or a synthetic peptide (SP-26) corresponding to amino acid residues 53-78 of bovine P 2 protein. The effects of transforming growth factor-β1 (TGF-β1) on the clinical signs, histological changes, cell-mediated immune responses, and secretion of interferon-γ (IFN-γ) by lymphoid cells of rats with EAN were examined. Systemic administration of TBF-β1 markedly inhibited the clinical signs and histological changes of EAN when given intraperitoneally every other day for Days 0 through 18. In addition, it decreased proliferative responses and reduced the delayed-type hypersensitivity (DTH) response to SP-26 compared to control rats. The reduction in clinical severity correlated with skin test unresponsiveness (DTH) to the disease-inducing agent (SP-26) as well to decreased cellular responsiveness to the antigen in vitro . The decrease in cellular responsiveness extended to a decrease in at least one T cell lymphokine, IFN-γ. The profound effect of TGF-β on disease progression in EAN, a T-cell-mediated process, is consistent with a direct effect of this growth factor on T lymphocytes.